Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.

ABSTRACT:

Purpose

Homologous recombination DNA repair deficiency (HRD) is associated with sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors in certain cancer types, including breast, ovarian, pancreatic, and prostate. In these cancers, BRCA1/2 alterations and genomic scar signatures are useful indicators for assessing HRD. However, alterations in other homologous recombination repair (HRR)-related genes and their clinical significance in other cancer types have not been adequately and systematically investigated.

Methods

We obtained data sets of all solid tumors in The Cancer Genome Atlas and comprehensively analyzed HRR pathway gene alterations, their loss-of-heterozygosity status, per-sample genomic scar scores, ie, the HRD score and mutational signat

SUBMITTER: Takamatsu S 

PROVIDER: S-EPMC9200383 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature